Licensing status

Publication and contact information

Drug platforms

2´-O-methyltransferase-deficient, live, attenuated dengue virus vaccine

2´-O-methyltransferase-deficient dengue virus could be used to develop live, attenuated vaccines against the infection. In mice and nonhuman primates, dengue virus serotypes 1 and 2 with loss-of-function mutations in 2´-O-methyltransferase were attenuated but still induced a protective immune response, including the production of neutralizing antibodies. In mice and nonhuman primates, vaccination with an attenuated dengue strain protected the animals from a subsequent challenge with a virulent strain. Next steps include evaluating the 2´-O-methyltransferase deficiency in dengue virus serotypes 3 and 4 and then developing a vaccine candidate that could protect against all four dengue virus serotypes.

SciBX 6(34); doi:10.1038/scibx.2013.942
Published online Sept. 5, 2013

Patent application filed; available for licensing from the Agency for Science, Technology and Research (A*STAR)

Züst, R. et al. PLoS Pathog.;
published online Aug. 1, 2013;
Contact: Katja Fink, Agency for Science, Technology and Research (A*STAR), Singapore
Contact: Pei-Yong Shi, Novartis Institute for Tropical Diseases, Singapore
Contact: Cheng-Feng Qin, Beijing Institute of Microbiology & Epidemiology, Beijing, China